Introduction to Vaccine Performance

In addition, the chitosan nanoparticle represents a promising adjuvant for DNA vaccine delivery, which improves the immune system stimulation and boosts the vaccine performance.

Continued vaccine development efforts will lead to secure supply of low-cost vaccines, and ongoing vaccine studies will provide critical vaccine performance data and inform optimal deployment strategies, in both routine use and in outbreak settings.

A safety signal in dengue seronegative vaccine recipients stimulated an international re-look at the vaccine performance profile, new World Health Organization recommendations for use, and controversy in the Philippines involving the government, regulatory agencies, Sanofi Pasteur, clinicians responsible for testing and administering the vaccine, and the parents of vaccinated children.

Until improved TB vaccines are available, it is crucial to use BCG in a manner which ensures optimal vaccine performance.

This paper describes the main conclusions of the Sixth Meeting of the International Dengue Initiative (IDI) held in June 2018, following release of a new product label by the manufacturer, updated WHO-SAGE recommendations, additional scientific evidence on vaccine performance, and reports of experiences by implementing countries.

The specific objectives of this meeting were to review vaccine-preventable diseases (VPDs) and vaccine performance in older adults and analyse the impact of the adult vaccination campaigns currently being implemented in Europe.

Vaccine performance was assessed by measuring immune responses to NP and M2, and monitoring weight loss and survival following influenza A challenge.

Although surveillance has increased, the medical community's understanding of seasonal influenza vaccine performance remains limited.

A vaccine candidate for HIV steps into phase III trials, signs emerge that antibiotics impair vaccine performance, and other highlights from clinical trials and laboratory studies.

Those biomarkers identified as resistance or susceptibility markers in CVL have been used to evaluate the vaccine performance against L.

Whether interventions can improve oral vaccine performance is uncertain.

CEPI is faced with complex decisions that involve confronting trade‐offs between multiple objectives, diverse stakeholder perspectives, and uncertainty in vaccine performance.

Recent analyses have shown that vaccine performance is dependent on serostatus.

To effectively monitor vaccine performance and effectiveness, robust molecular and phylogenetic techniques are essential to detect novel strain variants that might emerge due to vaccine pressure.

The National Technical Advisory Group on Immunization (NTAGI) is the advisory body that considers disease burden, vaccine performance, cost-effectiveness and potential for introduction into national programmes, reporting to the Ministry of Health.